Isospec raises USD 1.9 Million to revolutionize human health through rapid diagnostics
17.04.2024
Lausanne-based Isospec Analytics has secured USD 1.9 million in Pre-Seed Funding to advance its mission of revolutionizing human health. Their breakthrough biomolecular analysis technology promises scalable identification of unknown molecules, serving pharmaceutical, agritech, and nutrition sectors.
 Isospec Analytics Co-Founders
|
 |
Identifying unknown molecules in drug, nutrition, or pesticide development is crucial but often lengthy and unsuccessful. Leveraging 20 years of research, Isospec Analytics founders Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, fused technologies from analytical chemistry, photonics, and cryogenic materials to create a tool that rapidly generates new insights into molecular structures.
Isospec Analytics raised USD 1.9M in pre-seed funding led by Founderful (formerly Wingman Ventures), with Tiny.vc, another.vc, and Venture Kick also participating. The funds will fuel the company through its commercial phase.
The company's tech quickly identifies unknown molecules, transforming months into minutes. It's revolutionizing molecular identification, especially in food and agritech for quality control and R&D. But its true potential lies in discovering new biomarkers for therapy and diagnostics. The team is currently working on the scalability of their platform, introducing automation at every step and implementing machine learning tools for data analysis and insight generation.
Isospec Analytics Co-Founders Thomas Rizzo, Ahmed Ben Faleh and Stephan Warnke
Isospec Analytics raised USD 1.9M in pre-seed funding led by Founderful (formerly Wingman Ventures), with Tiny.vc, another.vc, and Venture Kick also participating. The funds will fuel the company through its commercial phase.
The company's tech quickly identifies unknown molecules, transforming months into minutes. It's revolutionizing molecular identification, especially in food and agritech for quality control and R&D. But its true potential lies in discovering new biomarkers for therapy and diagnostics. The team is currently working on the scalability of their platform, introducing automation at every step and implementing machine learning tools for data analysis and insight generation.
Isospec Analytics won the last stage of Venture Kick and participated in Venture Leaders Biotech in 2023.
“Venture Kick was instrumental in the development of Isospec Analytics. The funds from previous stages allowed us to acquire our first customers and further develop the technology and applications. Beyond the financial contribution, it provided us with the kick we needed to move fast via the different camps, workshops, and programs,” said Ahmed Ben Faleh, CEO of Isospec Analytics.
Isospec Analytics Co-Founders Thomas Rizzo, Ahmed Ben Faleh and Stephan Warnke